DISCLAIMER
This web site contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the company's control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

Date Title   09/03/10 Celgene Officially Notified of ANDA Filing for REVLIMID(R) SUMMIT, N.J., Sep 03, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization to manufacture and market generic versions of REVLIMID(R) (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States. Celgene intends to vigorous...  08/26/10 Celgene Corporation Announces Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer SUMMIT, N.J., Aug 26, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) todayannounced the appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer, effective September 27, 2010. Ms. Fouse will be responsible for all finance operations at Celgene and will report to Robert J. Hugin, Chief Executive Officer of Celgene Corporation. Fouse succeeds David W. Gryska, who served as Senior Vice President and Chief Finan...  08/25/10 Celgene Expects to Receive a Paragraph IV Notification of an ANDA Filing for REVLIMID(R) SUMMIT, N.J., Aug 25, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer. Celgene intend...  08/20/10 REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan BOUDRY, Switzerland, Aug 20, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients...  08/04/10 Celgene/Abraxis Receive Verbal Confirmation of Early Termination of Hart-Scott-Rodino (HSR) 30-Day Waiting Period SUMMIT, N.J., Aug 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regard to Celgene's pending acquisition of Abraxis Bioscience, Inc. (NASDAQ: ABII). Celgene anticipates that the transaction will be completed in the th...  07/29/10 Celgene Reports Record Second Quarter 2010 Operating and Financial Results Record Second Quarter Results Driven By Market Share Gains Across Major Markets REVLIMID(R) Second Quarter Global Net Product Sales Increased 48% Y/Y VIDAZA(R) Second Quarter Global Net Product Sales Increased 43% Y/Y Non-GAAP Second Quarter Diluted Earnings Per Share Increased 50% Y/Y SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GA...  07/19/10 Celgene Corporation to Announce Second Quarter 2010 Results on July 29, 2010 SUMMIT, N.J., Jul 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 29, 2010 at 9 a.m. ET to discuss the company's second quarter 2010 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated g...  06/30/10 Celgene to Acquire Abraxis BioScience Inc. ABRAXANE(R) Approved for Second-Line Use in Metastatic Breast Cancer, Establishes Celgene in Solid Tumors Complementing Its Leadership Position in Blood Cancers Recent Clinical Data Presented at ASCO and AACR for ABRAXANE in First-Line Non-small Cell Lung Cancer and First-Line Pancreatic Cancer Highlights Significant Growth Opportunities Celgene Reaffirms 2010 Non-GAAP Financial Outlook; Expects Acquisition to be Modestly Dilutive to Non-GAAP Earnings in...  06/24/10 Revlimid® Granted Approval for Treatment of Relapsed or Refractory Multiple Myeloma in Japan (June 24, 2010) – Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan. Multiple myeloma is the second m...  06/14/10 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J., Jun 14, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. On Thursday, June 17, 2010, Celgene will present at the Goldman Sachs 31st Annual Healthcare Conference at 10:00 a.m. PT. ...  06/12/10 Updated Results of Phase III Study Evaluating Continuous REVLIMID(R) Therapy in Newly Diagnosed Multiple Myeloma BOUDRY, Switzerland, Jun 12, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival (PFS), the primary endpoint of the study. The data were presented ...  06/07/10 Data from Study of Revlimid(R) in Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Presented at ASCO BOUDRY, Switzerland, Jun 07, 2010 (BUSINESS WIRE) --ABSTRACT #6508 Celgene International Sàrl (NASDAQ:CELG) today announced thatresearchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology. Results of the Phase II single-arm study reported that at a median follow-up of 23 months, the overall...  06/06/10 At ASCO, Oral Presentation from Intergroupe Francophone Du Myelome (IFM) of Phase III Study (IFM 2005 02) Evaluating Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the American Society of Clinical Oncology. Results of the study (IFM 2005 02) demonstrated that patients with multiple myeloma receiving continuous lenalidomide (REVLIMID) following a first-line autologo...  06/06/10 Oral Presentation at ASCO from Intergroup Phase III Study (CALGB 100104) Evaluates Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the annual meeting of the American Society of Clinical Oncology. Results of the Phase III, randomized, controlled, double-blind, multi-center clinical study of patient...  06/06/10 Randomized Phase III Study Comparing REVLIMID(R) Plus Melphalan and Prednisone (MPR) Compared to Autologous Stem Cell Transplant Presented at ASCO BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of lenalidomide plus low-dose dexamethasone (Rd) were presented at the Amer...  06/05/10 Data from Pomalidomide Study in Refractory Multiple Myeloma Patients Presented at ASCO BOUDRY, Switzerland, Jun 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results of a Phase II study of pomalidomide and dexamethasone in multiple myeloma patients who have failed both lenalidomide and bortezomib. Data were presented by Dr. Martha Lacy of the Mayo Clinic during the American Society of Clinical Oncology annual meeting. Patients with multiple myeloma who have progressed after multiple therapies have li...  06/04/10 Evaluation of REVLIMID(R) in Patients with Either GCB or Non-GCB Diffuse Large B-Cell Lymphoma Presented at ASCO BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced researchersat the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either with a germinal center B-cell (GCB) or non-germinal center B-cell (non-GCB) phenotype. Investigators retrospectively analysed pooled patient data f...  06/04/10 Data from Combination of REVLIMID(R) and Rituxan(R) in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma Presented at ASCO BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology. Patients in the study had previously untreated indolent NHL with stage III or IV...  05/28/10 Celgene Corporation to Present at Three Upcoming Investor Conferences SUMMIT, N.J., May 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at three upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. On Thursday, June 3, 2010, Celgene will present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference 20...  05/27/10 Celgene Announces Dismissal of Suit against Barr Laboratories Following Withdrawal of Thalidomide ANDA SUMMIT, N.J., May 27, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases. Celgene Corporation, headquartered in Summit, New Jers...  05/24/10 Celgene Corporation to Present at the 2010 Citi Global Health Care Conference SUMMIT, N.J., May 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi Global Health Care Conference on Wednesday, May 26, 2010 at 11:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated ...  05/21/10 More Than 100 Presentations and Posters Evaluating Celgene Products to Be Highlighted at Three Major Medical Meetings in June BOUDRY, Switzerland, May 21, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials evaluating Celgene products in blood cancers and solid tumors at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois from June 4-8. Additionally, clinical data will be presented on Celgene products in...  05/05/10 Celgene Corporation to Present at the Ninth Annual JMP Securities Research Conference SUMMIT, N.J., May 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Ninth Annual JMP Securities Research Conference on Monday, May 10, 2010 at 9:30 a.m. PT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an in...  04/29/10 Celgene Reports Record First Quarter 2010 Operating and Financial Results Record First Quarter Results Driven By Gains in Market Share and Duration of Therapy Across Global Markets REVLIMID(R) First Quarter Global Net Product Sales Increased 46% Y/Y VIDAZA(R) First Quarter Global Net Product Sales Increased 60% Y/Y Non-GAAP Diluted Earnings Per Share Increased 43% Y/Y SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 First Quarter Financial Results Year-Over-Year Non-GAAP...  04/29/10 Celgene Corporation Announces Senior Management Succession SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its senior management succession plan. As of the Company's annual meeting, scheduled on June 16, 2010, Dr. Sol J. Barer currently Chief Executive Officer, will be appointed Executive Chairman of the Board of Directors through December 31, 2010 and Robert J. Hugin, currently President and Chief Operating Officer, will be appointed Chief Executive Officer of Celgene Corporation. Dr. Barer has served a...  04/19/10 Celgene Corporation to Announce First Quarter 2010 Results on April 29, 2010 SUMMIT, N.J., Apr 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 29, 2010 at 9 a.m. ET to discuss the company's first quarter 2010 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated glo...  03/18/10 Celgene Corporation to Present at the Barclays Capital 2010 Global Healthcare Conference SUMMIT, N.J., Mar 18, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 at 10:45 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, ...  02/25/10 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J., Feb 25, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. On Wednesday, March 3, 2010, Celgene will present at the RBC Capital Markets 2010 Healthcare Conference at 8:00 a.m. ET. ...  01/28/10 Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals REVLIMID(R) Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q VIDAZA(R) Fourth Quarter Global Net Product Sales Increased 68% Y/Y and 13% Q/Q Full Year Non-GAAP Diluted Earnings Per Share Increased 33% Y/Y SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Y...  01/19/10 Celgene Corporation to Announce Fourth Quarter and Full-Year 2009 Results on January 28, 2010 SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 28, 2010 at 9 a.m. ET to discuss the company's fourth quarter and full-year 2009 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an ...  01/15/10 Celgene Completes Acquisition of Gloucester Pharmaceuticals Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 millionCommercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period u...  01/12/10 Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpoint BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that the Intergroupe Francophone du Myelome and University Hospital of Toulouse, the sponsor of the study, reported that the independent Data and Safety Monitoring Committee, of the international Phase III, randomized, double-blind, multi-center clinical study (IFM 2005 02) evaluating REVLIMID(R) (lenalidomide) compared to placebo in multi...  01/11/10 Celgene Corporation Reviews 2009 Achievements and Announces 2010 Financial Outlook _ Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals î REVLIMID(R) Fourth Quarter Global Net Product Sales Increased Nearly 35% Y/Y î VIDAZA(R) Fourth Quarter Global Net Product Sales Increased Nearly 65% Y/Y î Full Year Non-GAAP Diluted Earnings Per Share Increased More Than 30 % Y/Y î Conducting 20 Phase III and Pivotal Clinical TrialsSUMMIT, N.J., Jan 11, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG)...  01/06/10 Celgene Corporation to Present at the 28th Annual JPMorgan Healthcare Conference SUMMIT, N.J., Jan 06, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 28th Annual JPMorgan Healthcare Conference on Monday, January 11, 2010 at 8:00 AM PST (11:00 AM EST) will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgen...